Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ALCMI-005: Phase II Study of Pembrolizumab and Epacadostat for Small Cell Lung Cancer After Previous Treatment With Platinum-Based Therapy

NCT03402880 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT03402880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03402880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ALCMI-005: Phase II Study of Pembrolizumab and Epacadostat for Small Cell Lung Cancer After Previous Treatment With Platinum-Based Therapy
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Withdrawn
Start date
October 31, 2018
Completion date
October 3, 2018
Enrollment
0 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

extensive stage small cell lung carcinoma